What changes occur in visceral fat in HIV under an integrase inhibitor background?
Under integrase inhibitor treatment background, improvements in visceral fat, liver fat, and fat distribution indicators.[1] ↗
Human randomized trial subgroup; HIV-infected individuals
Small sample subgroup of specific HIV populations.
View the Article Title and Full Citation+
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England) · Volume/Issue Year 2024
First published 2024-06-20 · PMID 38905488
DOI 10.1097/qad.0000000000003965







